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TO THE EDITOR
Chronic, non-healing skin wounds such
as leg ulcers and pressure sores repre-
sent a significant clinical problem and a
financial burden to health-care systems.
For most patients, an underlying disease
interferes with normal tissue repair,
resulting in chronic wounds, which do
not heal as expected. At the molecular
level, excessive levels of matrix metal-
loprotease (Wysocki et al., 1993),
elastase activity (James et al., 2003),
and plasmin activity (Palolahti et al.,
1993; Lauer et al., 2000) in wound fluid
are characteristic of non-healing
wounds. The excessive protease activ-
ities degrade growth factors (Trengove
et al., 1999; Lauer et al., 2000) and
newly formed extracellular matrix
(Wysocki and Grinnell, 1990) and thus
contribute to perturbation of tissue
repair. Eventually, the wound becomes
deadlocked.
Clinical evidence is controversial
(Kjolseth et al., 1994; Vogt et al.,
2001) but some reports suggest that
aqueous polyvinyl pyrrolidone (PVP,
povidon)-iodine preparations can pro-
mote tissue repair in non-healing
wounds although the mechanisms re-
main unclear (Vogt et al., 2001).
Hypothesizing that PVP-iodine prepara-
tions reduce protease activity, we tested
the effect of different PVP-iodine doses
on the activity of selected proteases,
which have been proposed to be
critically involved in the pathophysio-
logy of chronic non-healing skin ulcers
(Palolahti et al., 1993; Wysocki et al.,
1993; James et al., 2003). Analysis was
performed in wound fluids, which were
obtained from different patients (n¼ 7)
presenting with chronic non-healing
venous leg ulcers. For fluid collection,
wounds were covered with a semi-
permeable polyurethane film for max-
imum 4 hours (Hydrofilms, Hartmann;
Heidenheim, Germany); fluids were
collected, centrifuged (10 minutes,
13,000 g, 41C), and frozen (801C)
until use. Protease analysis verified
highly elevated levels of neutrophil
elastase and plasmin activity in wound
fluids (Table 1). Neutrophil elastase
activity in serum of patients suffering
from chronic wounds was below
1.5 mU/ml, confirming the local synth-
esis of elastase activity within the
chronic wound environment.
First, we tested the effect of different
PVP-iodine doses on metalloprotease
activity. After development, the metal-
loproteases appear as transparent bands
in the gelatin zymography. There was a
clear reduction of metalloprotease ac-
tivity in PVP-iodine-treated wound
fluids (Figure 1). At 27105 M of
diluted PVP-iodine stock/10mg total
protein, metalloproteinase activity was
strongly inhibited and inhibition was
still noticeable at 14.7 105 M of
diluted PVP-iodine stock/10mg total
protein. We next analyzed inhibition
of neutrophil elastase and plasmin
activity with PVP-iodine. Already low
doses of PVP-iodine could significantly
inhibit purified plasmin and neutrophil
elastase activity (Figure 2a, *Po0.001).
When tested in wound fluid, there was
a clear dose-dependent inhibition of
neutrophil elastase activity by PVP-
iodine (Figure 2b). For plasmin, the
inhibition was less pronounced, and in
some samples almost missing. These
data indicate some sort of substrate
specificity for PVP-iodine action.
How can we explain our surprising
observations? PVP-iodine is a powerful
disinfectant with a broad microbicidal
spectrum, long history of use, and
absence of resistance development (re-
viewed by Fleischer and Reimer, 1997).
Microbicidal activity of PVP-iodine
at low concentrations becomes attenu-
ated in the presence of high protein
concentrations. Iodine is strongly oxi-
dative and easily reacts with the amino,
phenol, and –SH groups of amino acids,
Table 1. Protease activity in wound fluid obtained from venous stasis
ulcers
Wound fluid Elastase activity1 (mU/ml) Plasmin activity1 (mU/ml)
No. 1 41 202
No. 2 34 63
No. 3 131 45
No. 4 312 68
1Protease activity is normalized to total protein concentration.
Abbreviation: PVP, polyvinyl pyrrolidone
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with unsaturated fatty acids and nucleo-
tides. For enzymes, this results in
denaturation and loss of function and
we suspect that it is this mechanism we
observe in our experiments. In princi-
ple, this is a general mechanism not
specific for particular enzymes; how-
ever, the differences in plasmin and
elastase inactivation suggest that some
active centers are more susceptible to
iodine radical inactivation than others.
Nevertheless, our results suggest a
broad spectrum activity suitable for
the diverse and complex environment
of non-healing wounds.
PVP-iodine treatment of non-healing
wounds aims to reduce bacterial colo-
nization (Mandy 1985). Although the
effects on wound sanitation are limited
from clinical experience as most bac-
teria persist, PVP-iodine use became
controversial as in vitro research
showed marked cellular toxicity and
inhibition of normal wound healing in
some animal trials (Lineaweaver et al.,
1985a, b; Cooper et al., 1991; Smoot
et al, 1991). Toxicity data for non-
healing wounds appear more favorable
(Reimer et al., 2000; Vogt et al., 2001,
Fumal et al., 2002). The high protein
content in wound fluid may limit
diffusion of iodine radicals into
deeper parts of the wound and thus
limit cell damage. We suggest using
PVP-iodine in impaired wound healing
when healing is poorly progressing,
strongly exudating, and excessive
protease levels predominate. Once
this phase has given way to a healthy
granulation tissue and epithelial
migration occurs, this regimen may
be switched to moist wound healing
only.
From a clinical standpoint, this novel
activity of PVP-iodine for non-healing
wounds may explain the bene-
ficial effects for impaired healing
wounds. Our results may provide a
treatment rationale suitable not only
for those settings that can afford ex-
pensive modern wound dressings but
also for less privileged areas where
aqueous PVP-iodine may be readily
available.
The study adhered to the Declara-
tion of Helsinki Principles, was ap-
proved by the University of Cologne,
and patient consent was received.
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Figure 1. PVP-iodine inhibits metalloprotease activity in wound fluid obtained from non-healing
wounds. A 10 mg portion of total wound fluid protein (Pierce BCA assay, through Perbio Science, Bonn,
Germany) was incubated with 4ml of PVP-iodine serial dilutions as indicated (Mundipharma GmbH,
Limburg, Germany, or B Braun, Melsungen, Germany) in a total volume of 20ml. These dilutions of PVP-
iodine stock reflect the clinical practice of diluting PVP-iodine stock before application. After 30 minutes
at room temperature, metalloprotease activity was revealed by gelatin zymography. Treated wound fluid
was electrophoresed in gelatin-containing SDS gels. After washing, the renatured metalloproteases
degraded gelatin and appeared as clear, transparent bands after Commassie staining. Wound fluid
without PVP-iodine treatment is shown on the left lane. At PVP-iodine concentrations of 27 105 M/
10mg wound fluid protein, metalloprotease inhibition was very strong and even at 14.7 105 M/10 mg
still noticeable; the zymogram is representative of additional wound fluids tested; WF, wound fluid.
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Figure 2. PVP-iodine inhibits elastase and plasmin activity in wound fluid obtained from non-healing
wounds. (a) Human plasma plasmin (0.2 U/ml) (Roche, Mannheim, Germany) or human neutrophil
elastase (60 mU/ml) (Merck Biosciences, Darmstadt, Germany) or (b) wound fluids obtained from four
different patients (wound fluid nos. 1–4) was incubated with indicated concentrations of PVP-iodine at
room temperature for 30 minutes. Plasmin activity or neutrophil elastase activity was detected by
a plasmin (H-D-Val-Leu-Lys-AMC, Bachem, Weil a Rhein, Germany) or a neutrophil elastase
(MeOSuc-Ala-Ala-Pro-Val-AMC, Bachem) specific fluorescent peptide substrate; for analysis, equal
volumes of protease or wound fluid, PVP-iodine, and substrate solutions were added; protease activity
was detected by measuring the fluorescence at lex¼ 360 nm and lem¼465 nm in a spectrofluorometer
(Tecan Fluorescensreader Spectrafluor). Analysis was performed twice and samples were assayed
in triplicate; results are shown 7SD; an unpaired Student’s t-test was used to analyze differences
between groups; *Po0.001. Analyses are representative of additional wound fluids tested.
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